A phase II single-arm study of pazopanib and paclitaxel as first-line treatment for patients with advanced melanoma.

John P Fruehauf,David Hsiang,James G Jakowatz,Cameron Casey,Leonard S Sender,Claudette Bettis,Beverly Alger

doi:10.1200/jco.2014.32.15_suppl.9036

A phase II single-arm study of pazopanib and paclitaxel as first-line treatment for patients with advanced melanoma.

John P Fruehauf, David Hsiang + Show 5 more

https://doi.org/10.1200/jco.2014.32.15_suppl.9036

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2014
Citations: 2

Affiliation: University of California, Irvine Medical Center, University of California, Irvine

#Pazopanib In Combination #Metronomic Paclitaxel + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

9036 Background: We designed a phase II single arm, open label clinical trial evaluating pazopanib in combination with metronomic paclitaxel as first line therapy for subjects with unresectable sta...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.